

Supplemental Table 1. Baseline characteristics of covariates in the IPTW cohort of 955 eligible patients

Covariate	original cohort				IPTW cohort			
	Paxlovid group	Azvudine group	P	SMD	Paxlovid group	Azvudine group	P	SMD
n	451	504			953.45	956.53		
Age (mean (SD))	68.81 (17.40)	68.67 (15.05)	0.895	0.009	68.67 (17.43)	68.66 (14.99)	0.994	<0.001
Course (mean (SD))	8.82 (5.30)	9.13 (4.73)	0.329	0.063	9.05 (5.43)	9.01 (4.72)	0.908	0.008
3 doses of vaccination	412 (91.4)	475 (94.2)	0.107	0.112	885.8 (92.9)	887.2 (92.7)	0.930	0.006
SOFA score on Day 1 (mean (SD))	3.49 (1.78)	3.19 (1.76)	0.007	0.174	3.32 (1.78)	3.33 (1.82)	0.932	0.006
Immunocompromise status (%)	147 (32.6)	136 (27.0)	0.068	0.123	290.0 (30.4)	288.2 (30.1)	0.927	0.006
Tocilizumab (%)	30 (6.7)	21 (4.2)	0.118	0.11	52.4 (5.5)	53.2 (5.6)	0.966	0.003
Baricitinib (%)	20 (4.4)	20 (4.0)	0.844	0.023	41.6 (4.4)	42.2 (4.4)	0.971	0.002
Steroid (%)	364 (80.7)	339 (67.3)	<0.001	0.31	706.5 (74.1)	707.1 (73.9)	0.953	0.004
Immunoglobulins (%)	97 (21.5)	73 (14.5)	0.006	0.184	172.5 (18.1)	173.6 (18.2)	0.983	0.001
Antibiotic (%)	418 (92.7)	474 (94.0)	0.473	0.055	891.6 (93.5)	894.8 (93.5)	0.996	0.001
Bacteria (%)	81 (18.0)	84 (16.7)	0.658	0.034	164.0 (17.2)	164.2 (17.2)	0.976	<0.001
Candida (%)	126 (27.9)	143 (28.4)	0.938	0.01	271.2 (28.4)	271.2 (28.4)	0.976	0.002

Abbreviations: SOFA, Sequential Organ Failure Assessment.

